Cellectar Biosciences Inc CLRB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CLRB is a good fit for your portfolio.
News
-
Cellectar Biosciences’ Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom’s Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 Months
-
Cellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up to an Additional $73.3 Million
-
Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom’s Macroglobulinemia Market Landscape
-
Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides
-
Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update
-
Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day
-
Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024
Trading Information
- Previous Close Price
- $2.37
- Day Range
- $2.24–2.46
- 52-Week Range
- $1.56–4.45
- Bid/Ask
- $2.28 / $2.29
- Market Cap
- $82.09 Mil
- Volume/Avg
- 566,862 / 637,977
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 20
- Website
- https://www.cellectar.com
Valuation
Metric
|
CLRB
|
---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 8.32 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
CLRB
Financial Strength
Metric
|
CLRB
|
---|---|
Quick Ratio | 2.46 |
Current Ratio | 2.54 |
Interest Coverage | — |
Quick Ratio
CLRB
Profitability
Metric
|
CLRB
|
---|---|
Return on Assets (Normalized) | −247.90% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −1,159.46% |
Return on Assets
CLRB
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk A/S ADR
NVO
| Tlvpktcd | Csfrr | $565.6 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Wskwkswf | Qhwnyw | $127.8 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Lbcdfwm | Wprbdz | $117.3 Bil | |||
Moderna Inc
MRNA
| Pyfkrkzh | Slmlp | $46.1 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Xbxhnxbbd | Kqwlqss | $29.7 Bil | |||
argenx SE ADR
ARGX
| Rrgbwrxps | Zdlsq | $28.8 Bil | |||
BioNTech SE ADR
BNTX
| Jxwbwznxz | Rysm | $20.7 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Pycpnrpg | Sknlz | $16.1 Bil | |||
United Therapeutics Corp
UTHR
| Crmxndq | Dmv | $14.9 Bil | |||
Incyte Corp
INCY
| Nmtrpbj | Ghslw | $13.5 Bil |